top of page
Principal Investigators
Photo Eric 2018.jpg

Éric A. Cohen, PhD

CanCURE 2.0 Lead Investigator


Theme 2 & 3 Participant


Science Researcher

Bill Cameron, MD, FRCPC, FACP

Theme 3 Participant

Science Researcher

Cecilia Costiniuk, MD

Theme 2 Participant

Lead on the McGill Autopsy Biobank Initiative


Elie Haddad, MD

Theme 2 & 3 Participant


Emilia Liana Falcone, MD

Theme 1 & 3 Participant

Science Researcher

Mohammad-Ali Jenabian DVM, PhD

Theme 1 & 2 Participant


Christopher Power, PhD

Theme 2 Participant

Theme 1& 2 Participant

Steering Committee

CanCURE 2.0's Steering Committee (SC) includes the Team's seven Principal Investigators, as well as two Principle Knowledge Users that oversee and provide the community perspective. The SC is responsible for the overall management of the program and for setting scientific and training priorities.

K Fowke_official pic_edited.jpg

Keith Fowke,


Theme 1 Participant

Lead of Mentoring & Training Program


Mario A.


Theme 1 & 3 Participant

Lead on Autopsy Biospecimens & New Inhibitor Studies

SC members include:

Éric Cohen, SC Co-Chair, CanCURE 2.0 Lead Investigator, Principal Investigator

Jonathan Angel, SC Co-Chair, Principal Investigator

Petronela Ancuta, Principal investigator

Jérôme Estaquier, Principal Investigator

Thomas Murooka, Principal Investigator

Nicolas Chomont, Principal investigator

Jean-Pierre Routy, Principal Investigator

Ron Rosenes, Principle Knowledge User

Shari Margolese, Principle Knowledge User

SAB team

Eric J. Arts, PhD

Professor and Chair, Department of Microbiology and Immunology, Schulich School of Mecidine & Dentistry, Western University, London, On, Canada
Director, Ugandan CFAR Laboratories

E Arts_pic 2_edited.jpg
E Arts_pic 2_edited.jpg

Michael M. Lederman,MD

Scott R. Inkley Professor of Medicine, Professor of Pathology, Microbiology, Molecular Biology and Biomedical Ethics, School of Medicine, Case Western Reserve University, Cleveland, Oh, United States

E Arts_pic 2_edited.jpg

Guido Poli, MD

Professor and Head, AIDS Immunopathogenesis Unit, Division of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University School of Medicine & San Raffaele Scientifuc Institute, Milan, Italy

E Arts_pic 2_edited.jpg

Guido Silvestri, MD

Eminent Scholar in Comparative Pathology, Georgia Research AllianceProfessor of pathology and Laboratory Medicine, School of Medicine, Emory University, Chief, Division of Microbiology & Immunology, Yerkes National Primate Research Center, Atlanta, GA, United States

Scientific Advisory Board

CanCURE 2.0 is guided by a Scientific Advisory Board comprising four world-renowned basic and clinical scientists with a proven track record in the field of HIV Cure research.

Principle Knowledge Users

CAB team
shari crop 2.png

Shari Margolese

Principle Knowledge User

Community Advisory Board

renee crop.jpg

Renee Mashing

Community Advisor

tanguy (002).png

Tanguy Hedrich

Community-based research Coordinator

shari crop 2.png

José Sousa

Community Advisor

renee crop.jpg

Wangari Tharao

Community Advisor

Team Coordination
CC_Bio -Pictureistockphoto-1046691296-612x612.jpeg

Claudette Cardinal

Community Advisor

Team Coordination


Angela Durant

Project Manager



Clinical Trial Network

The CIHR Canadian HIV Trials Network (CTN) is an innovative partnership of clinical investigators, physicians, nurses, people living with HIV, pharmaceutical manufacturers and others that facilitate HIV clinical trials of the highest scientific and ethical standards.

ViiV Healthcare

Born out of a partnership between GSK and Pfizer in 2009, with Shionogi joining in 2012, ViiV Healthcare is determined to help end the HIV epidemic. Their one focused goal unites 1100 employees located across over 20 countries, with their expertise in research, manufacturing, policy and more. Viiv's current portfolio of 14 HIV treatments is thier first step in fighting back against the disease. ViiV Healthcare is dedicated to widening access to ensure those who need their medicines can receive them. Collaborations with organisations such as IASCHAI and MPP enable their medicines to make the greatest possible impact in countries around the world. 



Gilead's focuses on advancing the care of patients through its research and development efforts directly impacts our relationships with physicians, patients and their caregivers, and our employees. They provide physicians with the resources to better care for their patients by rapidly and efficiently discovering and developing innovative therapeutics. They collaborate with patient advocates, design drugs to enhance treatment regimens and implement effective patient assistance programs to ensure our efforts help meet the needs of patients and their caregivers.



Merck's vision is to make a difference in the lives of people globally through their innovative medicines, vaccines, and animal health products. They are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

Theratechnologies is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV.




BioLegend is a leading developer of cutting-edge antibodies and reagents provided for biomedical research worldwide. Their objective is to accelerate research and discovery by offering the highest quality products at an outstanding value, along with superior customer service and technical support. 

Affiliated Universities & research centers

bottom of page